PDX with Specific Genetic Alteration

Upon established 1500+ PDX models, LIDE has validated 200+ special drug resistant and/or genetic altered PDX models, including EGFR single/double/triple mutations in lung cancer, triple negative breast cancer, and models with KRAS mutation, HER2 amplification, or ALK/ROS1/NTRK fusion, etc.

Model#

Cancer

Gender

Age

Gene altered

Change

Resistant to

LD1-0025-200717

NSCLC

Male

54

EGFR

exon19del / T790M / C797S

Erlotinib / Osimertinib / Cetuximab / EAI045

LD1-2025-360947

NSCLC

Male

67

EGFR

19del (748-753) T790M C797S

AZD9291

PTEN

Y68X

PIK3CA

E726K

LD1-0025-200730

NSCLC

Male

60

EGFR

L858R 

Icotinib / AZD9291 / Afatinib

LD1-0025-360961

NSCLC

Female

47

EGFR

19del (746-750)

Erlotinib / AZD9291

LD1-0025-200662

NSCLC

Male

57 

EGFR

19del (748-753)

Erlotinib / AZD9291

c-met

amplification

LD1-0025-361336

NSCLC

Male

59

EGFR

19del

Gefitinib / AZD9291

c-met

amplification

LD1-0006-215676

NSCLC

Male

51

EGFR

L858R T790M

Erlotibib

LD1-0006-390629

NSCLC

Male

50

EGFR

19del

AZD9291

LD1-0006-360783

NSCLC

Male

57

EGFR

19del (746-748) T790M

Erlotibib

LD1-0006-217645

NSCLC

Female

62

EGFR

19del T790M

Gefitinib

LD1-0025-200630

NSCLC

Female

58 

EGFR

L858R

 

LD1-0025-200694

NSCLC

Female

68

EGFR

L858R

 

LD1-0006-215621

NSCLC

Female

71

EGFR

L858R

Gefitinib / Icotinib

LD1-0006-217655

NSCLC

Female

45

EGFR

19del (746-750)

 

LD1-0006-217683

NSCLC

 

 

EGFR

19del (745-749)

 

LD1-0025-200713

NSCLC

Female

48

EGFR

L858R

Gefitinib

LD1-0025-200739

NSCLC

Female

56

EGFR

19del (747-751)

Icotinib

LD1-0006-217643

NSCLC

Male

49

EGFR

L858R

Gefitinib

LD1-0025-360790

NSCLC

Male

53 

EGFR

19del (748-753)

 

LD1-0025-360811

NSCLC

male

——

EGFR

L858R

 

LD1-0020-360843

Glioblastoma

Male

42

EGFR

EGFRVIII mutation

 

LD1-0020-361574

Glioblastoma

Male

2

EGFR

EGFRVIII mutation

 

LD1-0020-200624

Glioblastoma

-

-

EGFR

EGFRVIII mutation

 

LD1-0011-200770

Cholangiocarcinoma

Female

47

FGFR2

BICC1--FGFR2 fusion

 

LD2-0009-200825

TNBC

Female

 

TNBC:HER2(-)ER(-)PR(-)

 

LD2-0009-200827

TNBC

Female

32

TNBC:HER2(-)ER(-)PR(-)

 

LD1-2009-362282

TNBC

Female

66

TNBC:HER2(-)ER(-)PR(-)

PTX resistant

LD1-2009-361918

TNBC

Female

59

TNBC:HER2(-)ER(-)PR(-)

 

LD1-2017-361443

Gastric cancer

Female

45 

Her2

+++(IHC)

Herceptin resistant

LD1-0025-360768

NSCLC

Female

54

HER2

p.G776delinsVC

 

LD1-0024-362394

Melanoma

Male

58

BRAF

V600E

PD-1 resistant

LD2-0012-200830

Colon cancer

Female

56 

BRAF

V600E

 

LD1-0038-200615

rectal cancer

Male

71 

BRAF

V600E

 

LD1-0029-361915

multiple myeloma

Male

62

BRAF

V600E

 

LD1-0036-360950

sarcoma

Male

19

BRAF

V600E

 

LD1-2012-362014

colon cancer

Male

48

BRAF

V600E

 

LD1-0006-390637

NSCLC

Male

58

ALK

EML4-ALK fusion;
L1196M mutation

Crizotinib

LD1-0036-361113

sarcoma

Female

42

NTRK3

EML4-NTRK3 fusion

 

LD1-0025-360715

NSCLC

Female

55

RET

KIF5B-RET fusion

 

LD1-0025-361384

NSCLC

Female

55

RET

KIF6B-RET fusion

 

LD1-0006-215625

NSCLC

Female

55

ALK

EML4-ALK

 

LD1-0006-215648

NSCLC

Female

47

ALK

EML4-ALK

 

LD1-0025-360815

NSCLC

female

55

ALK

EML4-ALK

 

LD1-0025-361002

NSCLC

male

48

ALK

EML4--ALK

 

LD1-0025-360807

NSCLC

female

60

MET

exon14 skipping

 

LD1-0025-361019

NSCLC

Female

64

ROS1

CD74-ROS1 fusion ROS1/G2032R mutation

Crizotinib

LD1-0025-361333

NSCLC

Male

55 

MET

CD47-MET fusion

 

LD1-0020-361404

Glioblastoma

Male

9

MET

PTPRZ1-MET fusion

 

LD1-0025-200756

NSCLC

Male

66

-

-

PD-L1(MPDL3280A)

LD1-0025-390663

NSCLC

Male

61

 

 

PD-L1 & AZD9291

LD1-0025-361384

NSCLC

Female

55 

 

 

PD-1(IBI308)

LD1-0025-362118

NSCLC

Male

37 

 

 

PD-1(Nivolumab)

LD1-0010-362343

cervical cancer

Female

 

 

 

PTX/carboplatin /  Nimotuzumab/PD-1

LD1-0032-361588

Ovarian cancer

Female

62

-

-

Cisplatin / 
PAPRi resistant (Niraparib/Olaparib)

LD1-0006-390655

Ovarian cancer

Female

 

-

-

Carboplatin

LD1-0038-361928

Rectal cancer

Female

26

-

-

cetuximab 

LD1-0012-361016

Colon cancer

Male

55

-

-

Avastin

LD2-6026-200614

DLBCL

Male

 

-

-

Rituximab

LD1-0029-361847

 multiple myeloma

Male

54

-

-

 

LD1-0006-370728

 multiple myeloma

Male

68

CD47+CD38+(FACS)

Bortezomib + dexamethasone

LD1-0009-362016

Breast cancer

Female

52

HER2(-)ER(+)PR(-)(clincial data)

PTX/palbociclib

LD1-0017-200636

Gastric cancer

Male

72

KRAS

G12C

 

LD1-0022-200791

Cholangiocarcinoma

Female

71

KRAS

G12C

 

LD1-0038-200642

Rectal cancer

 

 

KRAS

G12C

 

LD1-6038-200906

Colon cancer

Female

58

KRAS

G12C

 

LD1-0025-361646

lung cancer

Male

65 

KRAS

G12C

 

LD1-0020-361822

Pineoblastoma

Male

10

KRAS

G12C

 

LD1-0038-200631

Rectal cancer

Male

69 

KRAS

G12D

 

LD1-0038-200617

Rectal cancer

Male

80 

KRAS

G12D

 

LD1-0012-200644

colon cancer

Male

43 

KRAS

G12D

 

LD2-0033-200926

Pancreatic cancer

Male

58 

KRAS

G12D

 

LD2-0038-200823

Rectal cancer

-

-

KRAS

G12D

 

LD2-0033-200922

Pancreatic cancer

Male

55 

KRAS

G12D

 

LD2-0033-200923

Pancreatic cancer

Female

67 

KRAS

G12D

 

LD2-0012-201015

colon cancer

Female

75 

KRAS

G12D

 

LD1-0038-200638

Rectal cancer

-

-

KRAS

G12D

 

LD2-0033-200914

Pancreatic cancer

Male

38 

KRAS

G12D

 

LD2-0012-200837

colon cancer

Female

41 

KRAS

G12D

 

LD1-0038-200627

Rectal cancer

Male

48 

KRAS

G12D

 

LD1-0012-200670

colon cancer

Female

49 

KRAS

G12D

 

LD1-0033-361014

Pancreatic cancer

Male

64 

KRAS

G12D

 

LD2-0028-200621

 mucinous carcinoma

-

-

KRAS

G12D

 

LD2-0028-200620

 mucinous carcinoma

-

-

KRAS

G12D

 

LD1-2014-361357

endometrial cancer

Female

63 

KRAS

G12D

 

LD1-0032-361020

ovarian cancer

Female

54 

KRAS

G12D

 

LD1-0025-370740

lung cancer

Male

70 

KRAS

G12D

 

LD1-2038-362000

Rectal cancer

Male

54 

KRAS

G12D

 

LD1-0034-361136

prostate cancer

Male

59 

AR

AR-V7